Neos Settles with Teva Over ADHD Drug
Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT® under the Teva ANDA beginning on July 1, 2026, or earlier under certain circumstances.
Officials with Neos Therapeutics, Inc., have announced that they have entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals USA, Inc. to resolve all ongoing litigation involving Neos' patents protecting its Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets and Teva's Abbreviated New Drug Application (ANDA) filed with the US FDA to market a generic version of that product.
Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT® under the Teva ANDA beginning on July 1, 2026, or earlier under certain circumstances.
The settlement and licensing agreement is confidential and the agreement is subject to submission to the Federal Trade Commission and the US Department of Justice, the company noted in a press release.
